These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 9262393)

  • 21. The potential of exosomes in immunotherapy of cancer.
    Chaput N; Taïeb J; Schartz N; Flament C; Novault S; André F; Zitvogel L
    Blood Cells Mol Dis; 2005; 35(2):111-5. PubMed ID: 16027014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Generation of dendritic cell-based vaccines for cancer therapy.
    Reinhard G; Märten A; Kiske SM; Feil F; Bieber T; Schmidt-Wolf IG
    Br J Cancer; 2002 May; 86(10):1529-33. PubMed ID: 12085199
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced dendritic cell antigen presentation in RNA-based immunotherapy.
    Kalady MF; Onaitis MW; Padilla KM; Emani S; Tyler DS; Pruitt SK
    J Surg Res; 2002 Jun; 105(1):17-24. PubMed ID: 12069496
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dendritic cell-based tumor immunotherapy.
    Kadowaki N; Kitawaki T
    Rinsho Ketsueki; 2009 May; 50(5):358-63. PubMed ID: 19483395
    [No Abstract]   [Full Text] [Related]  

  • 25. A combination hybrid-based vaccination/adoptive cellular therapy to prevent tumor growth by involvement of T cells.
    Savai R; Schermuly RT; Pullamsetti SS; Schneider M; Greschus S; Ghofrani HA; Traupe H; Grimminger F; Banat GA
    Cancer Res; 2007 Jun; 67(11):5443-53. PubMed ID: 17545626
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy.
    Fassnacht M; Lee J; Milazzo C; Boczkowski D; Su Z; Nair S; Gilboa E
    Clin Cancer Res; 2005 Aug; 11(15):5566-71. PubMed ID: 16061874
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploiting alloreactivity for tumour immunotherapy.
    Stauss HJ; Xue S; Gillmore R; Gao L; Bendle G; Holler A; Downs AM; Morris E
    Vox Sang; 2004 Jul; 87 Suppl 2():227-9. PubMed ID: 15209922
    [No Abstract]   [Full Text] [Related]  

  • 28. Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.
    Tacken PJ; de Vries IJ; Torensma R; Figdor CG
    Nat Rev Immunol; 2007 Oct; 7(10):790-802. PubMed ID: 17853902
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mucin-1 is expressed on dendritic cells, both in vitro and in vivo.
    Cloosen S; Thio M; Vanclée A; van Leeuwen EB; Senden-Gijsbers BL; Oving EB; Germeraad WT; Bos GM
    Int Immunol; 2004 Nov; 16(11):1561-71. PubMed ID: 15381671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor-dendritic cell fusion technology and immunotherapy strategies.
    Shu S; Cohen P
    J Immunother; 2001; 24(2):99-100. PubMed ID: 11265778
    [No Abstract]   [Full Text] [Related]  

  • 31. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity.
    De Veerman M; Heirman C; Van Meirvenne S; Devos S; Corthals J; Moser M; Thielemans K
    J Immunol; 1999 Jan; 162(1):144-51. PubMed ID: 9886380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cytotoxic T lymphocyte priming versus cytotoxic T lymphocyte tolerance induction: a delicate balancing act involving dendritic cells.
    Melief CJ; Schoenberger S; Toes R; Offringa R
    Haematologica; 1999 Jun; 84 Suppl EHA-4():26-7. PubMed ID: 10907460
    [No Abstract]   [Full Text] [Related]  

  • 33. In vivo depletion of CD4+CD25+ regulatory T cells enhances the antigen-specific primary and memory CTL response elicited by mature mRNA-electroporated dendritic cells.
    Van Meirvenne S; Dullaers M; Heirman C; Straetman L; Michiels A; Thielemans K
    Mol Ther; 2005 Nov; 12(5):922-32. PubMed ID: 16257383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Induction of cytotoxic T lymphocytes against human cancer cell lines using dendritic cell-tumor cell hybrids generated by a newly developed electrofusion technique.
    Imura K; Ueda Y; Hayashi T; Itoh T; Shimizu K; Tamai H; Yano Y; Naito K; Kohara J; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H
    Int J Oncol; 2006 Sep; 29(3):531-9. PubMed ID: 16865268
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunogenic reactivity of CTLs induced by electrofusion cells of human dendritic cells and gastric cancer cells].
    Imura K; Hayashi T; Yano Y; Naito K; Kouhara J; Ueda Y; Nakane K; Matsuura Y; Takeda A; Takeda T; Kawai K; Yamagishi H
    Gan To Kagaku Ryoho; 2004 Oct; 31(11):1797-9. PubMed ID: 15553719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adoptive immunotherapy.
    Curti BD
    Cancer Chemother Biol Response Modif; 1997; 17():316-27. PubMed ID: 9551218
    [No Abstract]   [Full Text] [Related]  

  • 37. [Immunotherapy using dendritic cells for Helicobacter pylori infection].
    Otsu S; Nishizono A
    Nihon Rinsho; 2005 Nov; 63 Suppl 11():587-91. PubMed ID: 16363607
    [No Abstract]   [Full Text] [Related]  

  • 38. Exosomes in cancer immunotherapy: preclinical data.
    Andre F; Andersen M; Wolfers J; Lozier A; Raposo G; Serra V; Ruegg C; Flament C; Angevin E; Amigorena S; Zitvogel L
    Adv Exp Med Biol; 2001; 495():349-54. PubMed ID: 11774591
    [No Abstract]   [Full Text] [Related]  

  • 39. Dendritic cells in the treatment of cancer.
    Engleman EG
    Biol Blood Marrow Transplant; 1996 Oct; 2(3):115-7. PubMed ID: 9199753
    [No Abstract]   [Full Text] [Related]  

  • 40. Harnessing dendritic cells.
    Reis e Sousa C
    Semin Immunol; 2011 Feb; 23(1):1. PubMed ID: 21396569
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.